Sonia T. Oskouei, PharmD, BCMAS, DPLA, is vice president of Biosimilars for Cardinal Health.
Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?
Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.
US Rheumatologists Are Comfortable With Biosimilars, but Still Hesitant to Prescribe
Cardinal Health Specialty Solutions has produced a Rheumatology Insights report that includes results from a survey of over 100 US-based rheumatologists on their perceptions and experiences with biosimilars in rheumatology thus far.
2 Clarke Drive Cranbury, NJ 08512